U.S. flag

An official website of the United States government


Send to:

Choose Destination

Primary hyperparathyroidism

MedGen UID:
Concept ID:
Disease or Syndrome
Synonyms: Primary hyperparathyroidism (disease); Primary hyperthyroidism
SNOMED CT: Primary hyperparathyroidism (36348003)
HPO: HP:0008200
Monarch Initiative: MONDO:0010837
OMIM®: 168450


A type of hyperparathyroidism caused by a primary abnormality of the parathyroid glands (e.g., adenoma, carcinoma, hyperplasia). Primary hyperparathyroidism is associated with hyercalcemia. [from HPO]

Term Hierarchy

Conditions with this feature

Neonatal severe primary hyperparathyroidism
MedGen UID:
Concept ID:
Disease or Syndrome
Neonatal severe hyperparathyroidism usually manifests in the first 6 months of life with severe hypercalcemia, bone demineralization, and failure to thrive. Early diagnosis is critical because untreated NSHPT can be a devastating neurodevelopmental disorder, which in some cases is lethal without parathyroidectomy. Some infants have milder hyperparathyroidism and a substantially milder clinical presentation and natural history (summary by Egbuna and Brown, 2008).
Familial hypocalciuric hypercalcemia 3
MedGen UID:
Concept ID:
Disease or Syndrome
Any familial hypocalciuric hypercalcemia in which the cause of the disease is a mutation in the AP2S1 gene.
Hyperparathyroidism, primary, caused by water clear cell hyperplasia
MedGen UID:
Concept ID:
Disease or Syndrome
Familial hypocalciuric hypercalcemia 2
MedGen UID:
Concept ID:
Disease or Syndrome
Familial hypocalciuric hypercalcemia type II (HHC2) is an autosomal dominant disorder characterized by lifelong elevations of serum calcium concentrations with low urinary calcium excretion and normal circulating parathyroid hormone concentrations in most patients. Patients are generally asymptomatic (summary by Nesbit et al., 2013). For a general phenotypic description and a discussion of genetic heterogeneity of hypocalciuric hypercalcemia, see HHC1 (145980).
Hyperparathyroidism 1
MedGen UID:
Concept ID:
Disease or Syndrome
The spectrum of CDC73-related disorders includes the following phenotypes: Hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Primary hyperparathyroidism, the main finding of HPT-JT syndrome, occurs in up to 95% of affected individuals; onset is typically in late adolescence or early adulthood. HPT-JT-associated primary hyperparathyroidism is usually caused by a single parathyroid adenoma. In approximately 10%-15% of individuals, primary hyperparathyroidism is caused by parathyroid carcinoma. Ossifying fibromas of the mandible or maxilla, also known as cementifying fibromas and cemento-ossifying fibromas, occur in 30%-40% of individuals with HPT-JT syndrome. Although benign, these tumors can be locally aggressive and may continue to enlarge if not treated. Approximately 20% of individuals with HPT-JT syndrome have kidney lesions, most commonly cysts; renal hamartomas and (more rarely) Wilms tumor have also been reported. Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome. Parathyroid carcinoma. Most parathyroid carcinomas are functional, resulting in hyperparathyroidism and a high serum calcium level; however, nonfunctioning parathyroid carcinomas are also rarely described in individuals with a CDC73-related disorder. A germline CDC73 pathogenic variant has been identified in 20%-29% of individuals with apparently sporadic parathyroid carcinoma. Familial isolated hyperparathyroidism (FIHP). FIHP is characterized by primary hyperparathyroidism without other associated syndromic features. Individuals with CDC73-related FIHP tend to have a more severe clinical presentation and younger age of onset than individuals with FIHP in whom a CDC73 pathogenic variant has not been identified.
Multiple endocrine neoplasia type 4
MedGen UID:
Concept ID:
Neoplastic Process
Multiple endocrine neoplasia is a group of disorders that affect the body's network of hormone-producing glands called the endocrine system. Hormones are chemical messengers that travel through the bloodstream and regulate the function of cells and tissues throughout the body. Multiple endocrine neoplasia typically involves tumors (neoplasia) in at least two endocrine glands; tumors can also develop in other organs and tissues. These growths can be noncancerous (benign) or cancerous (malignant). If the tumors become cancerous, the condition can be life-threatening.\n\nThe major forms of multiple endocrine neoplasia are called type 1, type 2, and type 4. These types are distinguished by the genes involved, the types of hormones made, and the characteristic signs and symptoms.\n\nMany different types of tumors are associated with multiple endocrine neoplasia. Type 1 frequently involves tumors of the parathyroid glands, the pituitary gland, and the pancreas. Tumors in these glands can lead to the overproduction of hormones. The most common sign of multiple endocrine neoplasia type 1 is overactivity of the parathyroid glands (hyperparathyroidism). Hyperparathyroidism disrupts the normal balance of calcium in the blood, which can lead to kidney stones, thinning of bones, nausea and vomiting, high blood pressure (hypertension), weakness, and fatigue.\n\nMultiple endocrine neoplasia type 4 appears to have signs and symptoms similar to those of type 1, although it is caused by mutations in a different gene. Hyperparathyroidism is the most common feature, followed by tumors of the pituitary gland, additional endocrine glands, and other organs.\n\nThe most common sign of multiple endocrine neoplasia type 2 is a form of thyroid cancer called medullary thyroid carcinoma. Some people with this disorder also develop a pheochromocytoma, which is an adrenal gland tumor that can cause dangerously high blood pressure. Multiple endocrine neoplasia type 2 is divided into three subtypes: type 2A, type 2B (formerly called type 3), and familial medullary thyroid carcinoma (FMTC). These subtypes differ in their characteristic signs and symptoms and risk of specific tumors; for example, hyperparathyroidism occurs only in type 2A, and medullary thyroid carcinoma is the only feature of FMTC. The signs and symptoms of multiple endocrine neoplasia type 2 are relatively consistent within any one family.
Hyperparathyroidism 4
MedGen UID:
Concept ID:
Disease or Syndrome
Any familial isolated hyperparathyroidism in which the cause of the disease is a mutation in the GCM2 gene.

Professional guidelines


Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, Ebeling PR, Formenti AM, Frost M, Gosnell J, Lewiecki EM, Singer FR, Gittoes N, Khan AA, Marcocci C, Rejnmark L, Ye Z, Guyatt G, Potts JT
J Bone Miner Res 2022 Nov;37(11):2391-2403. Epub 2022 Oct 17 doi: 10.1002/jbmr.4682. PMID: 36054638
Zhu CY, Sturgeon C, Yeh MW
JAMA 2020 Mar 24;323(12):1186-1187. doi: 10.1001/jama.2020.0538. PMID: 32031566
Turner JJO
Clin Med (Lond) 2017 Jun;17(3):270-273. doi: 10.7861/clinmedicine.17-3-270. PMID: 28572230Free PMC Article

Recent clinical studies


das Neves MC, Santos RO, Ohe MN
Arch Endocrinol Metab 2022 Nov 11;66(5):678-688. doi: 10.20945/2359-3997000000557. PMID: 36382757Free PMC Article
Cormier C, Koumakis E
Joint Bone Spine 2022 Jan;89(1):105129. Epub 2021 Jan 20 doi: 10.1016/j.jbspin.2021.105129. PMID: 33484857
Newey PJ
Endocrinol Metab Clin North Am 2021 Dec;50(4):663-681. doi: 10.1016/j.ecl.2021.08.003. PMID: 34774240
Hollowoa BR, Spencer HJ 3rd, Stack BC Jr
Otolaryngol Head Neck Surg 2021 Sep;165(3):387-397. Epub 2021 Jan 19 doi: 10.1177/0194599820983728. PMID: 33461421
Kowalski GJ, Buła G, Żądło D, Gawrychowska A, Gawrychowski J
Endokrynol Pol 2020;71(3):260-270. doi: 10.5603/EP.a2020.0028. PMID: 32797471


Cusano NE, Cetani F
Arch Endocrinol Metab 2022 Nov 11;66(5):666-677. doi: 10.20945/2359-3997000000556. PMID: 36382756Free PMC Article
Kowalski GJ, Buła G, Żądło D, Gawrychowska A, Gawrychowski J
Endokrynol Pol 2020;71(3):260-270. doi: 10.5603/EP.a2020.0028. PMID: 32797471
Zhu CY, Sturgeon C, Yeh MW
JAMA 2020 Mar 24;323(12):1186-1187. doi: 10.1001/jama.2020.0538. PMID: 32031566
Muñoz-Torres M, García-Martín A
Med Clin (Barc) 2018 Mar 23;150(6):226-232. Epub 2017 Oct 6 doi: 10.1016/j.medcli.2017.07.020. PMID: 28992983
Bilezikian JP, Bandeira L, Khan A, Cusano NE
Lancet 2018 Jan 13;391(10116):168-178. Epub 2017 Sep 17 doi: 10.1016/S0140-6736(17)31430-7. PMID: 28923463


Pretorius M, Lundstam K, Heck A, Fagerland MW, Godang K, Mollerup C, Fougner SL, Pernow Y, Aas T, Hessman O, Rosén T, Nordenström J, Jansson S, Hellström M, Bollerslev J
Ann Intern Med 2022 Jun;175(6):812-819. Epub 2022 Apr 19 doi: 10.7326/M21-4416. PMID: 35436153
Sell J, Ramirez S, Partin M
Am Fam Physician 2022 Mar 1;105(3):289-298. PMID: 35289573
Kim SJ, Shoback DM
Endocrinol Metab Clin North Am 2021 Dec;50(4):609-628. doi: 10.1016/j.ecl.2021.07.006. PMID: 34774237
Muñoz-Torres M, García-Martín A
Med Clin (Barc) 2018 Mar 23;150(6):226-232. Epub 2017 Oct 6 doi: 10.1016/j.medcli.2017.07.020. PMID: 28992983
Carroll MF, Schade DS
Am Fam Physician 2003 May 1;67(9):1959-66. PMID: 12751658


Cormier C
Joint Bone Spine 2019 Jul;86(4):459-466. Epub 2018 Oct 6 doi: 10.1016/j.jbspin.2018.10.001. PMID: 30300686
Applewhite MK, White MG, Tseng J, Mohammed MK, Mercier F, Kaplan EL, Angelos P, Vokes T, Grogan RH
Surgery 2017 Jan;161(1):62-69. Epub 2016 Nov 17 doi: 10.1016/j.surg.2016.03.038. PMID: 27866715
Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP
Osteoporos Int 2017 Jan;28(1):1-19. Epub 2016 Sep 9 doi: 10.1007/s00198-016-3716-2. PMID: 27613721Free PMC Article
Fraser WD
Lancet 2009 Jul 11;374(9684):145-58. doi: 10.1016/S0140-6736(09)60507-9. PMID: 19595349
Rude RK
Otolaryngol Clin North Am 1996 Aug;29(4):663-79. PMID: 8844736

Clinical prediction guides

Zavatta G, Clarke BL
Endocrinol Metab (Seoul) 2021 Jun;36(3):525-535. Epub 2021 Jun 1 doi: 10.3803/EnM.2021.1061. PMID: 34107603Free PMC Article
Zhu CY, Nguyen DT, Yeh MW
Surg Clin North Am 2019 Aug;99(4):667-679. Epub 2019 May 11 doi: 10.1016/j.suc.2019.04.007. PMID: 31255198
Makras P, Anastasilakis AD
Metabolism 2018 Mar;80:57-65. Epub 2017 Oct 16 doi: 10.1016/j.metabol.2017.10.003. PMID: 29051042
Pappachan JM, Buch HN
Adv Exp Med Biol 2017;956:215-237. doi: 10.1007/5584_2016_26. PMID: 27864805
Duan K, Gomez Hernandez K, Mete O
J Clin Pathol 2015 Oct;68(10):771-87. Epub 2015 Jul 10 doi: 10.1136/jclinpath-2015-203186. PMID: 26163537

Recent systematic reviews

Nabata KJ, Wiseman JJ, Wiseman SM
Am J Surg 2023 Aug;226(2):186-196. Epub 2023 Apr 19 doi: 10.1016/j.amjsurg.2023.04.004. PMID: 37100740
Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M, Potts JT, Clarke BL, Brandi ML; International Workshop on Primary Hyperparathyroidism
J Bone Miner Res 2022 Nov;37(11):2293-2314. Epub 2022 Oct 17 doi: 10.1002/jbmr.4677. PMID: 36245251
Ejlsmark-Svensson H, Rolighed L, Harsløf T, Rejnmark L
Osteoporos Int 2021 Jun;32(6):1053-1060. Epub 2021 Feb 1 doi: 10.1007/s00198-021-05822-9. PMID: 33527175
Best CAE, Krishnan R, Malvankar-Mehta MS, MacNeil SD
Medicine (Baltimore) 2017 Oct;96(43):e7255. doi: 10.1097/MD.0000000000007255. PMID: 29068975Free PMC Article
Witteveen JE, van Thiel S, Romijn JA, Hamdy NA
Eur J Endocrinol 2013 Mar;168(3):R45-53. Epub 2013 Feb 20 doi: 10.1530/EJE-12-0528. PMID: 23152439

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...